[18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic io

• 作 者: Jansen NL Suchorska B Schwarz SB Eigenbrod S Lutz J Graute V Bartenstein P Belka C Kreth FW la Fougère C
• 机 构: Department of Nuclear Medicine, Ludwig-Maximilians-University Munich,
• 出 处: 中国神经肿瘤杂志
• 发表日期: 2013年02期
• 关键词: glioma progression iodine positron challenging prognostic prior tomographic seri

Therapy monitoring of glioma after stereotactic iodine-125 brachytherapy(SBT)remains challenging because posttherapeutic changes in magnetic resonance imaging can mimic tumor progression.We evaluated the prognostic value of serial[18F]fluoroethyltyrosine(FET)-positron emission tomographic(PET)scans for therapy monitoring of high-grade glioma(HGG)after SBT.Thirty-three patients with recurrent HGG were included.Serial FET-PET scans were performed prior to therapeutic intervention and at3-month intervals during the first year after SBT.FET-PET evaluation was performed by both conventional data analysis and kinetic

Therapy monitoring of glioma after stereotactic iodine-125 brachytherapy (SBT) remains challenging because posttherapeutic changes in magnetic resonance imaging can mimic tumor progression. We evaluated the prognostic value of serial [18F] fluoroethyltyrosine (FET) therapy monitoring of high-grade glioma (HGG) after SBT.Thirty-three patients with recurrent HGG were included.Serial FET-PET scans were performed prior to therapeutic intervention and at 3- month intervals during the first year after SBT.FET-PET evaluation was performed by both conventional data analysis and kinetic